David Planchard, Thoracic Oncologist and Professor at the University Paris Saclay, shared an article by Pasi A Jänne, et al. on X:
“Unparalleled benefit to date of osimertinib (FLAURA) and especially in combination with chemotherapy (FLAURA2) for our EGFR-mutated advanced NSCLC patients in first-line treatment with brain/meningeal metastases.”
A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.
Authors: Pasi A Jänne, et al.
